

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

483 M

Board of Directors

Mr Iain Ross
Chairman
Non-Executive Director

Mr Bryce Carmine
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

MARKET RELEASE

30th October 2017

NOVOGEN 2017 AGM: SHAREHOLDER Q+A AND WEBCAST

Sydney, 30th October, 2017, Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to submit questions ahead of the 2017 Annual General Meeting (AGM).

On the day of the AGM, shareholders in attendance will be invited to ask questions, and the Q+A from the live AGM will be interspersed with any questions received from shareholders ahead of the event.

To submit a question, please visit the Annual General Meetings page on our website and enter your question by close of business on Friday, 10th November 2017.

Submit a question here: <http://www.novogen.com/investorcentre/annualgeneralmeeting>.

AGM webcast

For those shareholders unable to attend the AGM in person, a copy of the CEO's AGM presentation and Q+A will be released to the ASX the following day.

AGM details

A reminder that the AGM is being held on 15 November from 2pm at the offices of K&L Gates, Level 31, 1 O'Connell St, Sydney.

To view a copy of the Notice of Meeting, please follow this link:

http://www.novogen.com/userfiles/documents/171016_Notice_of_Meeting-Novogen_Limited.pdf.

[ENDS]

Media and investor relations


Glen Zurcher

E: glen.zurcher@irdepartment.com.au

T: +61 420 249 299

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.



The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme (GBM). Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, TRXE-002-01 (Cantrixil) commenced a phase I clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

For more information, please visit: www.novogen.com.

